

CORZYNA™

(ranolazine 500 mg extended-release tablets)

CORZYNA™ Purchase Support Program

KYE recognizes the importance of access to new and important therapies for your patients. KYE also recognizes the importance of trialing a new medication to ensure it is tolerable and efficacious before a patient is asked to pay for it. As a result, **KYE is pleased to announce an enhanced CORZYNA™ Purchase Support Program (PSP) in conjunction with our partner PHARMEX Direct Inc. that will provide an initial 45-days of therapy with CORZYNA™ 500 mg tablets at no cost to your uninsured patients.**

The 45-day trial is a one-time offer for uninsured cash-paying patients who are newly enrolled in the PSP. Once the trial has ended, and together you have decided the benefits of continued therapy with CORZYNA™ have been demonstrated, the patient will simply need to start purchasing the product through the PSP at a significantly reduced cost of therapy.

To enroll patients in the CORZYNA™ Purchase Support Program, the steps are:

1. Physicians must fax a prescription for CORZYNA™ 500 mg to PHARMEX Direct at 905-847-8271.
2. Patients must register with PHARMEX Direct by phoning 1-800-663-8637 or visiting www.pharmexdirect.com/enroll.
3. A one-time 45-day supply of CORZYNA™ 500 mg will be delivered to the patient at no cost.
4. PHARMEX Direct will contact patients 7 days before the end of the trial to inquire if they will continue or discontinue therapy through the PSP.
5. If patients choose to continue therapy with CORZYNA™, they will receive supply at a 45% or greater discount to the regular price, depending on total daily dosage. The PSP price excludes shipping fees which are waived with a purchase of a 3-month supply.

For more information on CORZYNA™ or to book a call with your local representative please visit www.kyepharma.com or email CORZYNA@kyepharma.com.

CORZYNA™ (ranolazine extended-release tablets) is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies, including beta-blockers and calcium channel blockers.¹



¹CORZYNA™ Product Monograph (current), KYE Pharmaceuticals Inc.